8-K: Supernus Sets Q3 2025 Earnings Call for November 4

Supernus Pharmaceuticals announced it will report its third quarter 2025 financial and business results and host a conference call on November 4, 2025.

Summary

• Supernus Pharmaceuticals, Inc. expects to report its third quarter 2025 financial and business results after the market closes on Tuesday, November 4, 2025.
• A conference call and webcast will be hosted on Tuesday, November 4, 2025, at 4:30 p.m. E.T. to discuss these results.
• Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host the conference call.
• A live webcast will be available in the Events & Presentations section of the company's Investor Relations website at www.supernus.com/investors.
• Participants can pre-register for the call to receive a dial-in number with a personalized conference code.

Sentiment

Score: 5

Explanation: The filing is a neutral, procedural announcement regarding the scheduling of an earnings release and conference call, with no financial results or new strategic information disclosed.

Risks

• Ability to sustain and increase profitability.
• Ability to raise sufficient capital to fully implement corporate strategy.
• Implementation of corporate strategy.
• Future financial performance and projected expenditures.
• Ability to increase prescriptions for products, subsidiaries' products, and products acquired through Sage acquisition.
• Ability to increase net revenue from products, subsidiaries' products, and products acquired through Sage acquisition.
• Ability to commercialize products, subsidiaries' products, and products acquired through Sage acquisition.
• Ability to enter into future collaborations with pharmaceutical companies and academic institutions or obtain funding from government agencies.
• Product research and development activities, including timing and progress of clinical trials, and projected expenditures.
• Ability to receive, and timing of any receipt of, regulatory approvals for product candidates.
• Ability to protect intellectual property and operate without infringing on others' intellectual property rights.
• Expectations regarding federal, state, and foreign regulatory requirements.
• Therapeutic benefits, effectiveness, and safety of product candidates.
• Accuracy of estimates of market size and characteristics for product candidates.
• Ability to increase manufacturing capabilities for products and product candidates.
• Projected markets and growth in markets.
• Product formulations, patient needs, and potential funding sources.
• Staffing needs.
• Changes to laws and regulations applicable to the industry.
• Impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes, and tariffs.

Future Outlook

The press release includes standard forward-looking statements regarding the company's ability to sustain profitability, implement its corporate strategy, increase product prescriptions and revenue, commercialize products, secure collaborations, progress R&D activities, obtain regulatory approvals, protect intellectual property, and manage various market and regulatory risks. No specific financial guidance or estimates for Q3 2025 are provided in this announcement.

Management Comments

• Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host the conference call to present the third quarter 2025 financial and business results.

Industry Context

Supernus Pharmaceuticals operates in the biopharmaceutical sector, specifically focusing on developing and commercializing products for central nervous system (CNS) diseases. This announcement is a standard procedural update for publicly traded companies, informing investors of the upcoming release of quarterly financial performance, which is a key event for companies in the competitive pharmaceutical industry.

Stakeholder Impact

• Shareholders and investors will receive an update on the company's financial performance and business operations for Q3 2025 during the upcoming earnings call.
• Analysts will prepare for the earnings call to update their models and recommendations based on the forthcoming results.

Next Steps

• Supernus Pharmaceuticals will report its third quarter 2025 financial and business results on November 4, 2025.
• The company will host a conference call and webcast on November 4, 2025, at 4:30 p.m. E.T. to discuss the results.

Key Dates

Keywords

Supernus Pharmaceuticals, SUPN, Earnings Call, Financial Results, Q3 2025, Biopharmaceutical, CNS diseases, Investor Relations